Jane S. Ricciuti, RPh, MS


November 29, 2004

In This Article


The US Food and Drug Administration (FDA) approved 2 very different and new hormonal agents—Luveris (lutropin alfa) and Vantas (histrelin) Implant.

Lutropin alfa is approved for use in follicular stimulation in infertile hypogonadotropic hypogonadal women. Histrelin implant is approved for the palliative treatment of advanced prostate cancer.

This month's column reviews FDA new product approvals and labeling changes for:

Central Nervous System Agents

  • Imitrex (sumatriptan) Nasal Spray


  • Luveris (lutropin alfa) Subcutaneous Injection

  • Norditropin (somatropin) Injection

  • Saizen (somatropin) Injection

  • Vantas (histrelin) Implant


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.